

Resource Summary Report

Generated by [dkNET](#) on Aug 28, 2026

CDK2 (78B2) Rabbit mAb

RRID:AB_2276129

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 2546, RRID:AB_2276129

Antibody Information

URL: http://antibodyregistry.org/AB_2276129

Proper Citation: Cell Signaling Technology Cat# 2546, RRID:AB_2276129

Target Antigen: CDK2 (78B2) Rabbit mAb

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IP, F. Consolidation on 11/2018: AB_10695594, AB_10831366, AB_2276129.

Antibody Name: CDK2 (78B2) Rabbit mAb

Description: This monoclonal targets CDK2 (78B2) Rabbit mAb

Target Organism: rat, h, m, mouse, r, human, mk

Antibody ID: AB_2276129

Vendor: Cell Signaling Technology

Catalog Number: 2546

Record Creation Time: 20250819T222647+0000

Record Last Update: 20250820T021245+0000

Ratings and Alerts

No rating or validation information has been found for CDK2 (78B2) Rabbit mAb.

No alerts have been found for CDK2 (78B2) Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 42 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Dommer AP, et al. (2026) Cyclin E modulates vulnerability to CDC7 kinase inhibition. *Oncogenesis*, 15(1).

Nukaya M, et al. (2025) CDK7 is a novel therapeutic target in fibrolamellar carcinoma. *iScience*, 28(12), 113925.

Cha MC, et al. (2025) Anti-Cancer Effects of the Ethyl Acetate Fraction From *Opuntia humifusa* on Human Triple-Negative Breast Cancer Cells. *Integrative cancer therapies*, 24, 15347354251401187.

Hsu HE, et al. (2025) Phosphoproteomics of osimertinib-tolerant persister cells reveals targetable kinase-substrate signatures. *Molecular systems biology*, 21(11), 1547.

Zhu X, et al. (2025) Circular RNA circATM binds PARP1 to suppress Wnt/ β -catenin signaling and induce cell cycle arrest in gastric cancer cells. *Journal of advanced research*.

Liu C, et al. (2024) Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer. *Research square*.

Ramadan WS, et al. (2024) Design, synthesis and mechanistic anticancer activity of new acetylated 5-aminosalicylate-thiazolinone hybrid derivatives. *iScience*, 27(1), 108659.

Nasser AM, et al. (2024) CDKN2A/B Homozygous Deletion Sensitizes IDH-Mutant Glioma to CDK4/6 Inhibition. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(14), 2996.

Chen B, et al. (2024) Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer. *Oncogene*, 43(30), 2325.

Papadopoulos D, et al. (2024) The MYCN oncoprotein is an RNA-binding accessory factor of the nuclear exosome targeting complex. *Molecular cell*, 84(11), 2070.

Yip HYK, et al. (2024) Integrative modeling uncovers p21-driven drug resistance and prioritizes therapies for PIK3CA-mutant breast cancer. *NPJ precision oncology*, 8(1), 20.

Ji X, et al. (2024) Sphingolipid metabolism controls mammalian heart regeneration. *Cell metabolism*, 36(4), 839.

Müller L, et al. (2023) Plakophilin 3 facilitates G1/S phase transition and enhances proliferation by capturing RB protein in the cytoplasm and promoting EGFR signaling. *Cell*

reports, 42(1), 112031.

He W, et al. (2023) Modeling breast cancer proliferation, drug synergies, and alternating therapies. *iScience*, 26(5), 106714.

Li H, et al. (2023) Transgelin Promotes Glioblastoma Stem Cell Hypoxic Responses and Maintenance Through p53 Acetylation. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), e2305620.

Lim Y, et al. (2023) In silico protein interaction screening uncovers DONSON's role in replication initiation. *Science* (New York, N.Y.), 381(6664), eadi3448.

Gomes I, et al. (2023) Co-targeting RANK pathway treats and prevents acquired resistance to CDK4/6 inhibitors in luminal breast cancer. *Cell reports. Medicine*, 4(8), 101120.

Yu M, et al. (2023) FRMD8 targets both CDK4 activation and RB degradation to suppress colon cancer growth. *Cell reports*, 42(8), 112886.

DiPeri TP, et al. (2023) Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(21), 4385.

Golkowski M, et al. (2023) Multiplexed kinase interactome profiling quantifies cellular network activity and plasticity. *Molecular cell*, 83(5), 803.